Breakthrough Anti-Aging Drug Could Be Right Around The Corner
Researchers have zeroed in on a single, but significant, aspect of aging -- the decline in immune function. Scientists are testing the drug Rapamycin's effect on older people, according to MIT Technology Review.
Rapamycin, an immunosuppressant, was initially approved by the U.S. Food and Drug Administration to prevent the rejection of transplanted organs. Yet, experiments yielded results that showed that the drug extended the life span of yeast, worms, and mice.
Joan B. Mannick, the cofounder and chief medical officer of a biotech firm called resTORbio, is conducting clinical trials of a drug candidate intended to slow the age-related decline of the immune response.
When asked about potential results in their clinical trials, Mannick said, “They’re still on track for readouts in 2020.”
“The exciting thing about this, which I don’t know if the aging field has realized, is this is the farthest-along program of anything in the aging field. We have two phase III trials targeting the biology of aging, to prevent aging-related diseases in humans, that will have a readout in a year. That’s huge!” she said.
“The field is not a decade away,” Mannick added. “We don’t know yet, and we have to wait for the results of the trial. But if this result is positive and if health authorities approve this drug -- which are two ‘ifs’ -- we’ll have a product for people that is targeting the biology of aging to prevent aging-related diseases. Not just in our lifetime, but in, you know, a few years.”